CN116535500A - 马铃薯x病毒单克隆抗体pvx-6及其应用 - Google Patents
马铃薯x病毒单克隆抗体pvx-6及其应用 Download PDFInfo
- Publication number
- CN116535500A CN116535500A CN202211515142.2A CN202211515142A CN116535500A CN 116535500 A CN116535500 A CN 116535500A CN 202211515142 A CN202211515142 A CN 202211515142A CN 116535500 A CN116535500 A CN 116535500A
- Authority
- CN
- China
- Prior art keywords
- pvx
- monoclonal antibody
- potato
- virus
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000061456 Solanum tuberosum Species 0.000 title abstract description 37
- 235000002595 Solanum tuberosum Nutrition 0.000 title abstract description 37
- 241000700605 Viruses Species 0.000 title abstract description 30
- 241000709992 Potato virus X Species 0.000 claims abstract description 43
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 210000004408 hybridoma Anatomy 0.000 claims description 18
- 238000004321 preservation Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 238000008157 ELISA kit Methods 0.000 claims description 2
- 241000710007 Potexvirus Species 0.000 claims description 2
- 230000000984 immunochemical effect Effects 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 abstract description 22
- 101000714429 Potato virus X Coat protein Proteins 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 27
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 239000011248 coating agent Substances 0.000 description 20
- 238000000576 coating method Methods 0.000 description 20
- 238000004140 cleaning Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000011161 development Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000013256 coordination polymer Substances 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 239000012089 stop solution Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000012015 potatoes Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000208292 Solanaceae Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 241000554155 Andes Species 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了马铃薯X病毒单克隆抗体PVX‑6及其应用,单克隆抗体PVX‑6包括重链和轻链,重链氨基酸序列如SEQ ID NO.3所示;轻链氨基酸序列如SEQ ID NO.5所示,该抗体能够与PVX的CP蛋白(PVX‑CP)和PVX病毒粒子发生特异性反应,不与PVY病毒粒子或健康植株发生反应。进一步通过DAS‑ELISA方法检测配对情况,PVX‑6为包被抗体时,能与其他抗体配对成功,如PVX‑1、PVX‑3和PVX‑6;经灵敏度检测结果表明,PVX单克隆抗灵敏度均可以达到1:10240(w/v,g/mL)倍稀释,能够作为检测马铃薯X病毒抗体和检测试剂盒。
Description
技术领域
本发明涉及生物检测领域,具体涉及马铃薯X病毒单克隆抗体PVX-6,还涉及单克隆抗体PVX-6的应用。
背景技术
马铃薯(Solanum tuberosum L.)起源于南美洲安第斯山脉,茄科,一年生草本植物,无性繁殖、块茎可粮菜兼用,是全世界最重要的高产作物之一,仅次于小麦、水稻和玉米。我国是马铃薯第一生产大国,马铃薯种植面积及总产量均居世界首位,但单产水平远低于欧美等发达国家。
我国在2015年实施马铃薯主粮化战略以来,马铃薯战略地位得到进一步提升,而提高脱毒种薯质量及普及率成为产业健康发展的重要保障。而马铃薯作为无性繁殖作物,感染了病毒之后的马铃薯,由于连年种植,病毒将通过块茎世代传递,导致发病率逐年增加,产量迅速下降。在田间,马铃薯病毒可以通过汁液摩擦、蚜虫传毒等方式使无毒的马铃薯感染病毒,造成马铃薯的减产、退化。马铃薯感染病毒后会终生带毒,病情随着种植代数逐年加重,最后失去种植价值。
长期以来,病毒病一直困扰科研工作者,目前在马铃薯作物上发现的病毒种类有40多种,还包括一种类病毒。其中PVX是马铃薯X病毒属(Potexvirus)的成员,又称马铃薯普通花叶病毒或马铃薯轻花叶病毒,寄主范围较广,主要侵染茄科作物,PVX作为影响马铃薯种薯质量的主要有害生物之一,是判定马铃薯种薯质量是否合格的关键指标之一。
PVX单一侵染植株后,植株症状轻微花叶或潜隐,有时叶面稍有皱缩、叶缘波状,会造成少量的减产。但在田间种植时,常常发生复合侵染,当与PVY复合侵染马铃薯,症状加剧,使马铃薯产量大幅度降低,严重时可造成减产80%,导致严重的经济损失。
因此,建立简便、快速、灵敏、经济、准确的马铃薯病毒病检测技术,满足马铃薯种薯田间质量检测服务的需要,为马铃薯种薯质量检测认证工作的全面推进提供技术支持。
发明内容
有鉴于此,本发明的目的之一在于提供一种马铃薯X病毒单克隆抗体PVX-6;本发明的目的之二在于提供分泌抗马铃薯X病毒的单抗PVX-6的杂交瘤细胞;本发明的目的之三在于提供所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的试剂盒中的应用;本发明的目的之四在于提供所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的抗体中的应用;本发明的目的之五在于提供含有所述马铃薯X病毒单克隆抗体PVX-6的试剂盒。
为达到上述目的,本发明提供如下技术方案:
1、马铃薯X病毒单克隆抗体PVX-6,所述单克隆抗体PVX-6包括重链和轻链,所述重链氨基酸序列如SEQ ID NO.3所示;所述轻链氨基酸序列如SEQ ID NO.5所示。
本发明优选的,编码所述单克隆抗体PVX-6的重链的核苷酸序列如SEQ ID NO.4所示,编码所述轻链的核苷酸序列如SEQ ID NO.6。
2、分泌所述抗马铃薯X病毒的单抗PVX-6的杂交瘤细胞,其特征在于:所述杂交瘤细胞保存于中国典型培养物保藏中心,保藏号为CCTCC NO:C2022279,分类命名为杂交瘤细胞株3D6D9B5。
3、所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的试剂盒中的应用。
4、所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的抗体中的应用。
5、含有所述马铃薯X病毒单克隆抗体PVX-6的试剂盒。
本发明优选的,所述试剂盒为ELISA试剂盒、免疫化学试剂盒、免疫荧光试剂盒或Western Blot检测试剂盒。
本发明的有益效果在于:本发明公开了马铃薯X病毒单克隆抗体PVX-6,PVX-6重链氨基酸序列如SEQ ID NO.3所示;轻链氨基酸序列如SEQ ID NO.5所示。该抗体能够与PVX的CP蛋白(PVX-CP)和PVX病毒粒子发生特异性反应,不与PVY病毒粒子或健康植株发生反应。进一步通过DAS-ELISA方法检测配对情况,PVX-6为包被抗体时,能与其他抗体配对成功,如PVX-1、PVX-3和PVX-6;经灵敏度检测结果表明,PVX单克隆抗灵敏度均可以达到1:10240(w/v,g/mL)倍稀释,能够作为检测马铃薯X病毒抗体和检测试剂盒。
附图说明
为了使本发明的目的、技术方案和有益效果更加清楚,本发明提供如下附图进行说明:
图1为PVX-CP基因片段扩增(M:2K plusII marker;1、2:PVX-CP基因片段(714bp));
图2为PVX-CP表达(M:Marker;1:蛋白沉淀;2:蛋白上清;3:总蛋白;4:阴性对照);
图3为PVX-CP纯化(A:不同浓度咪唑洗脱PVX-CP,M:marker,1:50mM咪唑洗脱,2:100mM咪唑洗脱,3:300mM咪唑洗脱。B:PVX-CP纯化结果,M:marker,4:浓缩后蛋白);
图4为Western blot分析PVX单克隆抗体特异性(M:蛋白marker,1:健康马铃薯组培苗,2:感染PVX的马铃薯组培苗,3:感染PVY的马铃薯组培苗);
图5为PVX单克隆抗体灵敏度分析。
生物保藏:
将分泌PVX-6和PVX-2抗体的杂交瘤细胞送中国典型培养物保藏中心保藏,保藏地址为中国武汉武汉大学,分别命名为3D6D9B5、4C10F4F5;3D6D9B5保藏日为2022年9月1日,保藏号为CCTCC NO:C2022279,分类命名为杂交瘤细胞株3D6D9B5;4C10F4F5保藏日为2022年9月1日,保藏号为CCTCC NO:C2022280,分类命名为杂交瘤细胞株4C10F4F5。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好的理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
实施例1、病毒CP蛋白表达
(1)表达载体构建
在生物技术信息中心(National Center for Biotechnology Information,NCBI)上检索PVX的基因序列,根据PVX的CP蛋白基因全长序列设计扩增CP蛋白基因全长的引物(表1),将引物在NCBI上进行比对,比对后由上海生工生物工程技术服务有限公司合成。其中用PVX-CP-F与PVX-CP-R的引物扩增PVX-CP基因,扩增产物为714bp。
表1、PVX-CP扩增引物
以提取植物病毒总RNA为模板,按照试剂盒的说明进行操作合成cDNA,以合成的cDNA为模板,以表1中的引物进行扩增,反应体系为系为50μL,cDNA模板2μL,病毒上、下游引物(0.1μmol·L-1)各2μL,2×taq酶25μL,ddH2O补足至50μL。反应条件为94℃预变性5min,94℃变性30s,55℃退火30s,72℃延伸1min,循环35次,72℃延伸10min。
PVX-CP基因经PCR扩增后,利用琼脂糖凝胶电泳分析,检测到长度为714bp的DNA片段(图1),通过胶回收得到PVX-CP基因片段,将其连接到pET28a载体上,并转入BL21感受态细胞中,37℃倒置平板过夜培养后,挑选单克隆菌斑送至生工进行测序,经过序列比对,选择测序结果正确的菌液进行蛋白表达。
(2)大肠杆菌中表达及纯化
大肠杆菌中表达目的蛋白的方法如下:
a.将测序正确的大肠杆菌菌液加入5mL的LB液体培养基中,放入37℃恒温振荡培养箱,250rpm/min过夜培养16-18h,作为种子液;
b.按1:100转接到新鲜的200mL LB培养基中,37℃,250rpm/min条件培养,当菌液OD600=0.6时,补加IPTG诱导剂,分别于18℃继续诱导培养;
c.4℃,5000rpm/min,15min,收集菌体;
d.将菌体用裂解buffer(50mm Tris、0.5M NaCl,pH 8.0)重悬后进行超声破碎。超声条件为:work 3s,off 2s,时间15min,重复一遍;
e.超声后的样品,4℃,5000rpm/min,15min,分别取上清液和沉淀用SDS-PAGE胶进行蛋白分析,结果如图2所示。结果显示,重组蛋白PVX-CP可以表达。
病毒CP蛋白纯化的方法如下:
a.取培养后的菌体,加入裂解buffer(50mM Tris、0.5M NaCl,pH 8.0)重悬后进行超声破碎;超声条件为:work 3s,off 2s,时间15min,重复一遍;
b.将超声破碎后的菌液于低温离心机内离心,4℃,5000rpm/min,15min,收集上清,由于上清直接挂柱,为了使其不挂柱,故向上清中加入变性剂尿素,终浓度为8M,溶解后,于4℃静置1h,离心取上清;
c.将上述获得的上清液,用0.45μm滤膜过滤,通过Ni亲和层析柱进行蛋白纯化。步骤如下:
d.用5倍柱体积的去离子水洗涤,去除空气和20%乙醇;
e.5~10倍柱体积Buffer A平衡柱子,(Buffer A:50mM Tris、0.15M NaCl、8M尿素,pH 8.0);
f.将样品以0.5mL/min的速度流穿Ni柱;
g.用Buffer A平衡柱子;
h.分别用50mM咪唑、100mM、300mM咪唑洗脱。
i.将洗脱下来的样品分别进行SDS-PAGE胶分析是否有目的蛋白,结果如图3中A所示。
结果显示,不同浓度的咪唑均能将病毒CP蛋白洗脱下来,且100mM、300mM洗脱下来的病毒CP蛋白纯度更高。因此选择100mM、300mM咪唑洗脱的蛋白收集后稀释透析后浓缩,并用SDS-PAGE胶检测目的蛋白纯度,结果如图3中B所示,结果显示纯度很高。
实施例2、马铃薯X病毒单克隆抗体血清制备
(1)免疫小鼠
以实施例1制备的重组病毒CP蛋白为免疫原,选取健康Balb/c小鼠3只。首次免疫分别使用抗原50μg,每只分别与等体积的弗氏完全佐剂乳化后,腹部多点皮下注射免疫小鼠。第一次免疫后,每隔14d,用抗原50μg,每只和等体积的弗氏不完全佐剂乳化后,腹部多点皮下注射免疫小鼠,免疫3次。第三次免疫开始,每次免疫后7d进行小鼠眼眶静脉丛(或尾静脉)取血,通过间接ELISA测定小鼠血液抗体效价,检测方法如下:
(1)蛋白包被:实验组分别用ELISA包被液稀释PVX、PVY抗原蛋白至5μg/mL,对照组加ELISA包被液,100μL/孔,4℃包被过夜,PBST清洗2遍;
(2)封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
(3)加样:取血清稀释至指定浓度,100μL/孔,室温孵育1h,PBST清洗2遍;
(4)二抗:兔抗鼠IgG-HRP 1:1000,100μL/孔,室温孵育1h,PBST清洗3遍;
(5)显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
(6)终止:ELISA终止液,50μL/孔;
(7)读值:酶标仪主波长450nm,副波长630nm测定结果,结果如表2所示。
表2、小鼠血清效价
结果显示,2号小鼠的免疫效价最高。因此选择2号小鼠腹腔注射50μg抗原加强免疫,加强免疫3~7天,进行细胞融合实验。
(2)病毒单克隆杂交瘤细胞制备
细胞融合:
a.在生物安全柜中,收集生长旺盛、形态良好的骨髓瘤细胞(Sp2/0)约107个于50mL离心管中,不添加血清的DMEM(Glu 4.5g/L)培养基重悬,37℃培养箱预热;
b.加强免疫后3至7天的免疫合格小鼠,无菌条件下,取脾脏研磨过筛后离心收集脾细胞;
c.脾细胞与Sp2/0混匀离心后,用融合剂PEG1450进行化学融合,添加DMEM终止反应;
d.离心收集融合细胞,用添加NBS(新生牛血清)和HAT的高糖DMEM进行培养和筛选,约8天后用间接ELISA进行融合初筛,阳性细胞孔进行融合复筛;
e.选择稳定表达抗体的单克隆杂交瘤细胞,细胞扩大培养后,取细胞进行腹水生产,并冻存细胞。
细胞融合筛选
采用BSA竞争ELISA方法检测,步骤如下:
a.蛋白包被:分别用ELISA包被液稀释PVX抗原或X病毒研磨液至指定浓度,100μL/孔,4℃包被过夜,PBST清洗2遍;
b.封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
c.加样:原倍加入细胞上清,80μL,室温孵育1h,PBST清洗2遍;
d.二抗:兔抗鼠IgG-HRP 1:1000,100μL/孔,室温孵育1h,PBST清洗3遍;
e.显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
f.终止:ELISA终止液,50μL/孔;
g.读值:酶标仪主波长450nm,副波长630nm测定结果;
h.选择生活力良好,进行第一次亚克隆。
本次细胞融合获得20株阳性细胞,具体见表3:
表3、2号小鼠融合筛选
细胞亚克隆筛选:
用有限稀释法进行细胞克隆化。将阳性细胞重悬取细胞计数,以每200μL培养基含1个细胞为准则,按计数结果将阳性细胞稀释,每孔200μL加入96孔板中。7至9天后镜检观察,标记出现单一细胞簇孔。进行间接ELISA法检测阳性细胞。检测方法如下:
a.蛋白包被:实验组分别用ELISA包被液稀PVX或PVY抗原蛋白至1μg/mL,对照组加ELISA包被液,100μL/孔,4℃包被过夜,PBST清洗2遍;
b.封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
c.加样:取原倍细胞上清,80μL/孔,室温孵育1h,PBST清洗2遍;
d.二抗:兔抗鼠IgG-HRP 1:1000,100μL/孔,室温孵育1h,PBST清洗3遍;
e.显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
f.终止:ELISA终止液,50μL/孔;
g.读值:酶标仪主波长450nm,副波长630nm测定结果;
h.选择稳定表达抗体的单克隆杂交瘤细胞,细胞扩大培养后,取细胞进行腹水生产,并冻存细胞。
经过2次细胞亚克隆,仅挑选镜检单克隆和二克隆进行检测,获得6株阳性单克隆杂交瘤细胞株(表4),进行细胞扩大培养,取细胞进行腹水生产,并冻存细胞。
表4、亚克隆结果
(3)马铃薯病毒单克隆抗体制备
腹水制备:
腹腔注射致敏剂液体石蜡0.5mL/只,7天后腹腔注射阳性杂交瘤细胞,每株细胞打一只小鼠。每只小鼠注射105~106个细胞,离心收集的细胞用1×PBS缓冲液重悬后进行注射。直至第8天起可观察到小鼠腹腔微隆,继续饲养至腹腔涨圆到行动不便时,用引流法多次收集腹水,离心后于-80℃冻存。
腹水纯化:取腹水,用PBS稀释并过滤(0.22μm),取过滤后的样品,通过Protein G柱进行蛋白纯化。步骤如下:
a)用5倍柱体积的去离子水洗涤,去除空气和20%乙醇;
b)5~10倍柱体积buffer平衡柱子,buffer:PB缓冲液;
c)将样品以0.5mL/min的速度流穿Protein G柱;
d)用上述buffer平衡柱子;
e)用甘氨酸洗脱,并用Tris中和。
f)收集上述甘氨酸洗脱的样品,于4℃透析(透析Buffer:PBS)过夜。
g)取透析后的样品,用超滤法(超滤管)浓缩,并用SDS-PAGE胶检测目的蛋白纯度。
h)对纯度达到要求的抗体进行性能检测。
单克隆抗体性能检测:
a)蛋白包被:用ELISA包被液分别稀释PVX-CP、X病毒研磨液、Y病毒研磨液、健康组织研磨液,100μL/孔,4℃包被过夜,PBST清洗2遍;
b)封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
c)加样:取PVX单克隆抗体稀释至指定浓度,100μL/孔,室温孵育1h,PBST清洗2遍;
d)一抗:兔抗鼠IgG-HRP 1:1000,100μL/孔,室温孵育1h,PBST清洗3遍;
e)显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
f)终止:ELISA终止液,50μL/孔;
g)读值:酶标仪主波长450nm,副波长630nm测定结果,结果如表5所示。
表5、PVX单克隆抗体性能检测
结果显示,PVX-CP与X病毒吸光度均大于阴性对照2倍,并且Y病毒不与PVX单克隆抗体产生交叉反应,PVX单克隆抗体性能可用。
单克隆抗体特异性检测:
a)总蛋白提取:分别取0.1g植物组织,液氮研磨,加入250μL总蛋白提取液与5μL50×蛋白酶抑制剂;
b)13000rpm,4℃离心15min,吸取上清液;
c)上清液加入loading buffer后混匀,沸水煮10min,冷却5min,4℃13000rpm离心10min;
d)配制10%SDS-PAGE分离胶和5%浓缩胶,加样后180V电泳至loading buffer跑出;
e)电泳结束前将PVDF膜在甲醇中浸泡15s;
f)电泳结束后,将胶在转膜液中浸泡15min,进行转膜。100V转膜1~1.5h;
g)转好膜后用TBST清洗一次,用丽春红染色拍照,再用TBST清洗几次后,用TBST配制的5%脱脂奶粉进行封闭,室温封闭1h;
h)封闭完后加入1:5000稀释的一抗,4℃孵育过夜;
i)一抗反应完全后,用TBST进行洗膜,4次,每次15min;
j)加入1:5000稀释的二抗,室温孵育1h;
k)二抗反应完全后用TBST洗膜,4次,每次10min;
l)加入ECL显色液进行拍照,结果如图4所示。
结果显示,PVX-1、PVX-2、PVX-3、PVX-4、PVX-5和PVX-6单克隆抗体进均可以与感染PVX的马铃薯组培苗的蛋白提取液发生特异性免疫反应,不与感染PVY的马铃薯组培苗蛋白提取液发生特异性免疫反应,也不与健康的马铃薯组培苗蛋白提取液发生特异性免疫反应。
单克隆抗体配对检测:
a)蛋白包被:分别用ELISA包被液稀释PVX单克隆抗体至1μg/mL,100μL/孔,4℃包被过夜,PBST清洗2遍;
b)封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
c)加样:PVX组织500倍稀释,阴性组织500倍稀释,100μL/孔,室温孵育1h,PBST清洗2遍;
d)一抗:分别将标生物素的PVX、PVY抗体稀释至1μg/mL,100μL/孔,室温孵育1h,PBST清洗2遍;
e)二抗:Avidin-HRP 1:10000,100μL/孔,室温孵育1h,PBST清洗3遍;
f)显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
g)终止:ELISA终止液,50μL/孔;
h)读值:酶标仪主波长450nm,副波长630nm测定结果,结果如表5所示。
表5、PVX单克隆抗体配对结果
注:*为配对成功
单克隆抗体灵敏度检测:
a)蛋白包被:用ELISA包被液稀马铃薯病毒组培苗研磨液,1:10~1:163840倍梯度稀释,对照组加ELISA包被液,100μL/孔,4℃包被过夜,PBST清洗2遍;
b)封闭:配制3%脱脂奶粉,380μL/孔,室温孵育1h,PBST清洗2遍;
c)加样:取血清稀释至指定浓度,100μL/孔,室温孵育1h,PBST清洗2遍;
d)二抗:兔抗鼠IgG-HRP 1:1000,100μL/孔,室温孵育1h,PBST清洗3遍;
e)显色:TMB显色液A液:B液=1:1,100μL/孔,室温反应20min;
f)终止:ELISA终止液,50μL/孔;
g)读值:酶标仪主波长450nm,副波长630nm测定结果,结果如图5所示。
结果显示,用PVX进行包被,应用直接ELISA方法检测,PVX单克隆抗体灵敏度可以达到1:10240倍稀释。
为确定各个单克隆抗体的灵敏度,按照上述方法,区别是分别使用不同浓度的PVX-1、PVX-2、PVX-3、PVX-4、PVX-5和PVX-6单克隆抗体的进行检测,结果如表6所示。
表6、PVX单克隆抗体灵敏度检测
结果显示,PVX-6单克隆抗体的灵敏度最高,其次为PVX-2单克隆抗体,后续选择PVX-6和PVX-2。
对PVX-6和PVX-2进行测序,PVX-6的重链氨基酸序列如SEQ ID NO.3所示,编码该氨基酸的核苷酸序列如SEQ ID NO.4所示,PVX-6的轻链氨基酸序列如SEQ ID NO.5所示,编码该氨基酸的核苷酸序列如SEQ ID NO.6所示。PVX-2的重链氨基酸序列如SEQ ID NO.7所示,编码该氨基酸的核苷酸序列如SEQ ID NO.8所示,PVX-2的轻链氨基酸序列如SEQ IDNO.9所示,编码该氨基酸的核苷酸序列如SEQ ID NO.10所示。
选择产生PVX-6和PVX-2抗体的杂交瘤细胞送中国典型培养物保藏中心,保藏地址为中国武汉武汉大学,分别命名为3D6D9B5、4C10F4F5;3D6D9B5保藏日为2022年9月1日,保藏号为CCTCC NO:C2022279,分类命名为杂交瘤细胞株3D6D9B5;4C10F4F5保藏日为2022年9月1日,保藏号为CCTCC NO:C2022280,分类命名为杂交瘤细胞株4C10F4F5。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (7)
1.马铃薯X病毒单克隆抗体PVX-6,其特征在于:所述单克隆抗体PVX-6包括重链和轻链,所述重链氨基酸序列如SEQ ID NO.3所示;所述轻链氨基酸序列如SEQ ID NO.5所示。
2.马铃薯X病毒单克隆抗体PVX-6,其特征在于:编码所述单克隆抗体PVX-6的重链的核苷酸序列如SEQ ID NO.4所示,编码所述轻链的核苷酸序列如SEQ ID NO.6。
3.分泌权利要求1或2所述抗马铃薯X病毒的单抗PVX-6的杂交瘤细胞,其特征在于:所述杂交瘤细胞保存于中国典型培养物保藏中心,保藏号为CCTCC NO:C2022279,分类命名为杂交瘤细胞株3D6D9B5。
4.权利要求1所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的试剂盒中的应用。
5.权利要求1所述马铃薯X病毒单克隆抗体PVX-6在制备检测马铃薯X病毒的抗体中的应用。
6.含有权利要求1所述马铃薯X病毒单克隆抗体PVX-6的试剂盒。
7.根据权利要求6所述的试剂盒,其特征在于:所述试剂盒为ELISA试剂盒、免疫化学试剂盒、免疫荧光试剂盒或Western Blot检测试剂盒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211515142.2A CN116535500B (zh) | 2022-11-30 | 2022-11-30 | 马铃薯x病毒单克隆抗体pvx-6及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211515142.2A CN116535500B (zh) | 2022-11-30 | 2022-11-30 | 马铃薯x病毒单克隆抗体pvx-6及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116535500A true CN116535500A (zh) | 2023-08-04 |
CN116535500B CN116535500B (zh) | 2024-03-22 |
Family
ID=87451197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211515142.2A Active CN116535500B (zh) | 2022-11-30 | 2022-11-30 | 马铃薯x病毒单克隆抗体pvx-6及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116535500B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116589567A (zh) * | 2022-11-30 | 2023-08-15 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016049036A1 (en) * | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
WO2018129261A1 (en) * | 2017-01-05 | 2018-07-12 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
CN112912105A (zh) * | 2018-08-31 | 2021-06-04 | 因维克蒂斯股份有限公司 | 针对多种hla-g同种型的嵌合抗原受体 |
CN116183912A (zh) * | 2022-11-30 | 2023-05-30 | 西南大学 | 马铃薯x病毒纳米模拟酶试纸条及其应用 |
CN116589567A (zh) * | 2022-11-30 | 2023-08-15 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
-
2022
- 2022-11-30 CN CN202211515142.2A patent/CN116535500B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016049036A1 (en) * | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
WO2018129261A1 (en) * | 2017-01-05 | 2018-07-12 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
CN112912105A (zh) * | 2018-08-31 | 2021-06-04 | 因维克蒂斯股份有限公司 | 针对多种hla-g同种型的嵌合抗原受体 |
CN116183912A (zh) * | 2022-11-30 | 2023-05-30 | 西南大学 | 马铃薯x病毒纳米模拟酶试纸条及其应用 |
CN116589567A (zh) * | 2022-11-30 | 2023-08-15 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
Non-Patent Citations (2)
Title |
---|
TAO, W 等: ""immunoglobulin heavy chain, partial [Mus musculus]"", 《GENBANK》, 26 July 2016 (2016-07-26), pages 51070 * |
郭素华 等: ""抗马铃薯X病毒单克隆抗体的制备"", 《内蒙古大学学报(自然科学版)》, no. 4, 31 December 1990 (1990-12-31), pages 578 - 581 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116589567A (zh) * | 2022-11-30 | 2023-08-15 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN116535500B (zh) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111153991A (zh) | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 | |
CN114230660B (zh) | 抗大口黑鲈虹彩病毒lmbv的单克隆抗体及其应用 | |
CN116589567B (zh) | 马铃薯x病毒单克隆抗体pvx-2及其应用 | |
CN112111006B (zh) | 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒 | |
CN116535500B (zh) | 马铃薯x病毒单克隆抗体pvx-6及其应用 | |
CN110845582B (zh) | 一种猫细小病毒重组蛋白及其单克隆抗体的制备 | |
Wu et al. | Monoclonal antibodies against the whitefly-transmitted tomato yellow leaf curl virus and their application in virus detection | |
CN109971726B (zh) | 杂交瘤细胞株及其产生的抗体和制备方法 | |
CN111487417A (zh) | Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 | |
CN102590503B (zh) | 一种猪细环病毒ⅱ型抗体间接阻断elisa检测试剂盒 | |
CN116535502B (zh) | 特异性结合口蹄疫病毒o型的单克隆抗体在制备检测试剂盒中的应用 | |
CN114014916B (zh) | 猪圆环病毒3型Cap重组蛋白、其编码基因及在ELISA抗体检测中的应用 | |
CN112898422B (zh) | 一种烟草环斑病毒单克隆抗体及其制备方法和应用 | |
CN102533664A (zh) | 分泌抗水稻黑条矮缩病毒单抗杂交瘤细胞株及其单抗应用 | |
CN114280306B (zh) | 牛筋草epsps蛋白elisa检测试剂盒及检测方法 | |
CN116338193A (zh) | 一种基于抗体捕获的非洲马瘟间接elisa抗体检测试剂盒及其应用 | |
CN112342198A (zh) | PAT/pat单抗杂交瘤细胞株、产生的抗体及其制备方法 | |
CN110205300A (zh) | Bar单抗杂交瘤细胞株、产生的抗体及其制备方法 | |
Jordan et al. | Development of polyclonal and monoclonal antibodies to Rose rosette virus nucleoprotein | |
CN110981969A (zh) | 一种alv-k的elisa试剂盒及其检测方法 | |
CN115725511B (zh) | 一种杂交瘤细胞株R2McAb2A1及其分泌的单克隆抗体和应用 | |
CN112321707B (zh) | 一种马秋波病毒的特异性识别抗体及检测试剂盒 | |
Nguyen-ha et al. | Production of polyclonal antisera for diagnosis of rice yellow stunt virus (RYSV) in Vietnam. | |
CN116068174A (zh) | 一种地黄花叶病毒双抗体夹心酶联免疫检测试剂盒及制备与检测方法 | |
CN115678858A (zh) | 分泌抗马铃薯帚顶病毒单抗杂交瘤细胞株及其单抗应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |